Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	356.07M
Revenue (ttm)	196.49M
Net Income (ttm)	-259.47M
Shares Out	68.08M
EPS (ttm)	-3.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	932,817
Open	5.22
Previous Close	5.22
Day's Range	5.09 - 5.39
52-Week Range	1.58 - 19.95
Beta	-0.70
Analysts	Buy
Price Target	7.60 (+45.32%)
Earnings Date	Nov 7, 2024

About AMLX

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 384
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Forecast

According to 7 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is $7.6, which is an increase of 45.32% from the latest price.

Price Target

$7.6

(45.32% upside)

Analyst Consensus: Buy